Moreover, UGCG mRNA is upregulated in T-cells in response to treatment with IFNβ and fingolimod [53] - another immunomodulatory drug used for the treatment of RRMS—strongly suggesting that therapeutic intervention modulates glycosphingolipid biosynthesis. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.